Literature DB >> 16723293

Severe pulmonary hypertension in postmenopausal obese women.

Agne Taraseviciute1, Norbert F Voelkel.   

Abstract

CONTEXT: Severe pulmonary hypertension (PH) is a rare disorder triggered by a variety of factors and disease conditions and characterized by a shared pathophysiology. Two decades ago it was widely held that "primary" (idiopathic) pulmonary hypertension (PPH) is a disease of young women. However, we noticed recently in the UCHSC Pulmonary Hypertension Center that women with severe PH are frequently postmenopausal and overweight or obese.
OBJECTIVES: To determine whether severe PH is a disease not only of young women but also of postmenopausal women who are overweight or obese. DESIGN, SETTING, AND PARTICIPANTS: The medical records of 541 postmenopausal female patients at the UCHSC Pulmonary Hypertension Center were reviewed. The patients were divided into two groups based on their diagnosis of either primary or secondary PH. MAIN OUTCOME MEASURES: The medical records of postmenopausal women with severe PH were further reviewed for history of diabetes, systemic hypertension, and the use of anti-depressants, hormone replacement therapy, combination of anti-depressants and hormone replacement therapy, as well as anorexigens. Laboratory data such as elevated cholesterol, elevated uric acid, and elevated C-reactive protein (CRP) were recorded in these patients, as well as physical exam data to determine the body-mass index (BMI) of the patients.
RESULTS: 56% of all pulmonary hypertensive women who were patients at the UCHSC Pulmonary Hypertension Center were postmenopausal. 39% of postmenopausal women with PPH and 48% with secondary severe PH were obese. In addition, postmenopausal obese women frequently had systemic hypertension and were on hormone replacement therapy as well as antidepressant medication.
CONCLUSIONS: Obesity, hormone replacement therapy and anti-depressant therapy may contribute to the development of severe PH in genetically predisposed women. Further investigation, in the form of a prospective, case-control study, is needed to determine whether these factors exert a causative effect in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723293

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  27 in total

1.  Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.

Authors:  Meiqian Weng; Michael J Raher; Patricio Leyton; Terry P Combs; Philipp E Scherer; Kenneth D Bloch; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2010-11-12       Impact factor: 6.914

2.  Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey.

Authors:  Charles D Burger; Aimee J Foreman; Dave P Miller; Robert E Safford; Michael D McGoon; David B Badesch
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

3.  Insulin resistance in pulmonary arterial hypertension.

Authors:  R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

4.  Estrogen rescues preexisting severe pulmonary hypertension in rats.

Authors:  Soban Umar; Andrea Iorga; Humann Matori; Rangarajan D Nadadur; Jingyuan Li; Federica Maltese; Arnoud van der Laarse; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

Review 5.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

6.  Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity.

Authors:  Eric E Kelley; Jeff Baust; Gustavo Bonacci; Franca Golin-Bisello; Jason E Devlin; Claudette M St Croix; Simon C Watkins; Sonia Gor; Nadiezhda Cantu-Medellin; Eric R Weidert; Jefferson C Frisbee; Mark T Gladwin; Hunter C Champion; Bruce A Freeman; Nicholas K H Khoo
Journal:  Cardiovasc Res       Date:  2014-01-02       Impact factor: 10.787

7.  Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension.

Authors:  M Weng; D M Baron; K D Bloch; A D Luster; J J Lee; B D Medoff
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-09       Impact factor: 5.464

Review 8.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

9.  Effect of Bariatric Surgery on the Cardiovascular System in Obese Cases with Pulmonary Hypertension.

Authors:  Ahmed Abdallah Salman; Mohamed Abdalla Salman; Hossam El-Din Shaaban; Ahmed Abdelsalam; Mohamed Tourky; Samah M Lotfy; Haitham S E Omar; Mohamed Saber Mostafa; Mohammed A Nafea; Ahmed Abd El Aal Sultan; Mohammed Hassan Elshafey; Abdoh Salem; Walid Rafat Abdelaty; Osama Osman Khaliel; Hani Maurice Sabri Mikhail
Journal:  Obes Surg       Date:  2020-07-16       Impact factor: 4.129

Review 10.  Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation.

Authors:  Seiichiro Sakao; Koichiro Tatsumi; Norbert F Voelkel
Journal:  Respir Res       Date:  2009-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.